Medical Oncology

Herbert Ira Hurwitz, MD

Adjunct Professor in the Department of Medicine
Campus mail 439 Seeley-Mudd Bldg, 10 Bryan Searle Drive, Duke University M, Durham, NC 27710
Phone (919) 681-6006
Email address hurwi004@mc.duke.edu

Particular Clinical Interests and Skills: Phase I clinical trials involving new anti cancer drugs; drug combinations; and combinations of new drugs with radiation; cancers of the GI system

Education and Training

  • Clinical Oncology Fellow, Medicine, Johns Hopkins University, 1992 - 1996
  • Medical Resident, Medicine, Michael Reese Hospital & Medical Center, 1988 - 1991
  • M.D., Thomas Jefferson University, 1988

Grants

Publications

Meric-Bernstam, F, Hurwitz, H, Raghav, KPS, McWilliams, RR, Fakih, M, VanderWalde, A, Swanton, C, Kurzrock, R, Burris, H, Sweeney, C, Bose, R, Spigel, DR, Beattie, MS, Blotner, S, Stone, A, Schulze, K, Cuchelkar, V, and Hainsworth, J. "Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study." The Lancet Oncology 20, no. 4 (April 1, 2019): 518-530.

Full Text

Mettu, NB, Niedzwiecki, D, Rushing, C, Nixon, AB, Jia, J, Haley, S, Honeycutt, W, Hurwitz, H, Bendell, JC, and Uronis, H. "A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors." March 20, 2019.

PMID
30895346
Full Text

Hurwitz, HI, Tan, BR, Reeves, JA, Xiong, H, Somer, B, Lenz, H-J, Hochster, HS, Scappaticci, F, Palma, JF, Price, R, Lee, JJ, Nicholas, A, Sommer, N, and Bendell, J. "Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)." The Oncologist (December 14, 2018).

PMID
30552157
Full Text

Loupakis, F, Hurwitz, HI, Saltz, L, Arnold, D, Grothey, A, Nguyen, QL, Osborne, S, Talbot, J, Srock, S, and Lenz, H-J. "Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer." British Journal of Cancer 119, no. 12 (December 2018): 1451-1455.

PMID
30487637
Full Text

Innocenti, F, Jiang, C, Sibley, AB, Etheridge, AS, Hatch, AJ, Denning, S, Niedzwiecki, D, Shterev, ID, Lin, J, Furukawa, Y, Kubo, M, Kindler, HL, Auman, JT, Venook, AP, Hurwitz, HI, McLeod, HL, Ratain, MJ, Gordan, R, Nixon, AB, and Owzar, K. "Genetic variation determines VEGF-A plasma levels in cancer patients." Scientific Reports 8, no. 1 (November 5, 2018): 16332-null.

PMID
30397360
Full Text

Liu, Y, Starr, MD, Brady, JC, Rushing, C, Pang, H, Adams, B, Alvarez, D, Theuer, CP, Hurwitz, HI, and Nixon, AB. "Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105." Molecular Cancer Therapeutics 17, no. 10 (October 2018): 2248-2256.

PMID
29997150
Full Text

Hainsworth, JD, Meric-Bernstam, F, Swanton, C, Hurwitz, H, Spigel, DR, Sweeney, C, Burris, H, Bose, R, Yoo, B, Stein, A, Beattie, M, and Kurzrock, R. "Reply to J.J. Tao et al." Journal of Clinical Oncology 36, no. 23 (August 10, 2018): 2451-null. (Letter)

Full Text

Hurwitz, H, Van Cutsem, E, Bendell, J, Hidalgo, M, Li, C-P, Salvo, MG, Macarulla, T, Sahai, V, Sama, A, Greeno, E, Yu, KH, Verslype, C, Dawkins, F, Walker, C, Clark, J, and O'Reilly, EM. "Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies." Investigational New Drugs 36, no. 4 (August 2018): 683-695.

PMID
29508247
Full Text

Vlahovic, G, Meadows, KL, Hatch, AJ, Jia, J, Nixon, AB, Uronis, HE, Morse, MA, Selim, MA, Crawford, J, Riedel, RF, Zafar, SY, Howard, LA, O'Neill, M, Meadows, JJ, Haley, ST, Arrowood, CC, Rushing, C, Pang, H, and Hurwitz, HI. "A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer." The Oncologist 23, no. 7 (July 2018): 782-790.

PMID
29572245
Full Text

Chen, DS, and Hurwitz, H. "Combinations of Bevacizumab With Cancer Immunotherapy." Cancer Journal (Sudbury, Mass.) 24, no. 4 (July 2018): 193-204.

PMID
30119083
Full Text

Pages